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Summary
Background: In 2013, a systematic review and Delphi consensus reported that
specific probiotics can benefit adult patients with irritable bowel syndrome (IBS) and
other gastrointestinal (GI) problems.
Aim: To update the consensus with new evidence.
Methods: A systematic review identified randomised, placebo-controlled trials pub-
lished between January 2012 and June 2017. Evidence was graded, previously
developed statements were reassessed by an 8-expert panel, and agreement was
reached via Delphi consensus.
Results: A total of 70 studies were included (IBS, 34; diarrhoea associated with antibi-
otics, 13; diarrhoea associated with Helicobacter pylori eradication therapy, 7; other
conditions, 16). Of 15 studies that examined global IBS symptoms as a primary end-
point, 8 reported significant benefits of probiotics vs placebo. Consensus statements
with 100% agreement and “high” evidence level indicated that specific probiotics help
reduce overall symptom burden and abdominal pain in some patients with IBS and
duration/intensity of diarrhoea in patients prescribed antibiotics or H. pylori eradica-
tion therapy, and have favourable safety. Statements with 70%-100% agreement and
“moderate” evidence indicated that, in some patients with IBS, specific probiotics help
reduce bloating/distension and improve bowel movement frequency/consistency.
Conclusions: This updated review indicates that specific probiotics are beneficial in
certain lower GI problems, although many of the new publications did not report ben-
efits of probiotics, possibly due to inclusion of new, less efficacious preparations.
Specific probiotics can relieve lower GI symptoms in IBS, prevent diarrhoea associated
with antibiotics and H. pylori eradication therapy, and show favourable safety. This
study will help clinicians recommend/prescribe probiotics for specific symptoms.
The Handling Editor for this article was Professor Alexander Ford, and this uncommissioned review was accepted for publication after full peer-review.
Authors’ complete affiliations are listed in Appendix 1.
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1 | INTRODUCTION
In 2013, the European Society for Primary Care Gastroenterology
(ESPCG) published an evidence-based international guide for the
use of probiotics in the management of specific lower gastro-
intestinal (GI) symptoms.1 This guide was based on the results of
a systematic review of evidence regarding the use of probiotics vs
placebo in randomised controlled trials (RCTs). A Delphi panel
assessed this evidence and developed a number of consensus
statements. Since the publication of these statements, numerous
relevant clinical studies of probiotics in the management of lower
GI symptoms have been published. In the light of the new
evidence available in this rapidly evolving field, the objectives of
this publication are to update the systematic review and Delphi
consensus, and to incorporate the new findings into the
guidelines.
The importance of gut microbiota in health and disease is
becoming increasingly evident, and there is a growing body of
literature on the therapeutic potential of probiotics in GI
disorders2,3 like irritable bowel syndrome (IBS) and many other
conditions. The proposed mechanisms of action for the beneficial
effects of probiotics include competitive exclusion of pathogenic
microorganisms, inhibition of pathogen adhesion, production of
anti-microbial substances and modulation of the immune system.4-6
Studies in several animal models have indicated positive therapeu-
tic results for probiotics in a range of conditions, such as asthma,7
obesity,8,9 diabetes mellitus,10 hypertension,11,12 and depression
and anxiety;13 however, definitive data from human studies are
relatively sparse. There is some evidence for a beneficial effect of
probiotics in humans in the prevention of hypertension14 and
improvement of the symptoms of schizophrenia,15 depression16
and Alzheimer’s disease,17 although further studies are needed to
confirm these findings. Evaluation of the effect of probiotics in
humans is complex due to differences in strains, patient popula-
tions and dosing. In addition, many clinical trials report conflicting
findings, and results of meta-analyses have been published that
compare non-identical probiotic strains, making the evidence diffi-
cult to interpret. A transparent and rigorous methodology is
needed when evaluating the evidence because this topic remains
complex.
Lower GI symptoms commonly require a visit to a physician,
but the heterogeneity of symptoms presented and their underlying
causes may limit the pharmacological treatment options offered
because no single dominant drug therapy would be effective in all
cases. Although new pharmacological treatments are emerging,
challenges remain in terms of their ability to improve symptoms
without incurring side effects.18-21 Current evidence suggests that
probiotics in the diet may play a role in reducing uncomfortable
lower GI symptoms in adults. Therefore, as before, the emphasis of
the ESPCG updated evidence-based guidelines is on the potential
role of probiotics in the management of lower GI symptoms in
clinical practice.
2 | METHODS
2.1 | Design
The repeated consensus procedure was based on an updated
systematic literature review and re-rating of statements by an expert
panel.
2.2 | Systematic literature search
Placebo-controlled RCTs evaluating the effects of probiotics on
lower GI symptoms were identified through a systematic literature
review (based on Appraisal of Guidelines, Research and Evaluation
[AGREE] II criteria22) capturing studies published since the original
searches were conducted in January 2012.1 The same search terms
were used as in the original review to search Embase, MEDLINE
In-Process & Other Non-Indexed Citations and Ovid MEDLINE
(1946-present). A search was performed in July 2016 to identify
publications from 1 January 2012 to 28 July 2016. To keep this
publication as current as possible, an updated database search was
performed in June 2017.
2.3 | Citation screening and full-text review
Identified publications were screened manually based on the title
and abstract in accordance with 2009 Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines23
against predefined eligibility criteria (Table 1). Full-text versions of all
publications meeting the eligibility criteria at initial screening were
reviewed to confirm eligibility.
2.4 | Data items collected and quality assessment
The same data items were collected and tabulated as in the original
systematic review, including patient demographics, sample size, strain
of probiotic, setting, primary and secondary endpoints, and results.
Of note, the term “probiotics” has been used throughout this publi-
cation to refer to products that contain probiotics, regardless of
whether these are single or multiple strains. The additional step of a
quality assessment was performed for each publication (in both the
original and the updated review) using a modified version of the
Critical Appraisal Skills Programme (CASP) Checklist for Randomised
Controlled Trials,24 as recommended by the National Institute for
Health and Care Excellence.25
2.5 | Delphi consensus
A modified Delphi process was used to review the original
consensus statements in the light of the new evidence identified in
the current updated systematic review. The Delphi process uses
anonymous and iterative feedback and voting to achieve consensus
among a panel of independent experts by means of stepwise
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refinement of responses. The Consensus Group consisted of 10 pri-
mary care physicians with an interest in gastroenterology drawn
from the ESPCG, with the addition of 2 members from secondary
care; 7 of these individuals had taken part in the original consensus.
The Group was advised by a nonvoting Chair (APSH) who, in com-
mon with the members of the Consensus Group, has experience of
systematic reviews and guideline development. For this update, the
Steering Committee (APSH, CRM, PW and NdW) reviewed the origi-
nal statements in the light of the new evidence, and agreed to keep
them unchanged for the voting.
The Grading of Recommendations Assessment, Development and
Evaluation (GRADE) system26 was used by the Chair and Steering
Committee to rate the level of supporting evidence and the strength
of each statement. Using the GRADE system, each statement was
rated as follows: high—further research is unlikely to change our
confidence in the estimate of effect; moderate—further research is
likely to have an important impact on our confidence in the estimate
of effect and may change the estimate; low—further research is very
likely to have an important impact on our confidence in the estimate
of effect and is likely to change the estimate; and very low—any
estimate of effect is very uncertain.
The Consensus Group members reviewed both the original and
new evidence on the use of probiotics in the management of lower
GI symptoms. It was anticipated that 3 rounds of anonymous voting
would be required to achieve consensus. Votes were cast using an
online platform (Google Forms) and the results were analysed by the
nonvoting Chair. For each statement, voters indicated their level of
agreement on a scale from 1 to 6 (1 = strongly disagree; 2 = dis-
agree with major reservation; 3 = disagree with minor reservation;
4 = agree with major reservation; 5 = agree with minor reservation;
and 6 = strongly agree). Consensus was defined a priori as agree-
ment by at least 67% of respondents. In some cases, the consensus
statement is indication-specific; however, studies in other indications
that provide relevant data are also described for completeness. In
the following discussion, “significant” refers to a statistically signifi-
cant result (P < 0.05).
After the updated consensus was completed, 3 consensus state-
ments covering general considerations related to probiotic use in
daily practice which referenced no specific studies individually
(Statements 14, 15 and 16 in the original consensus) were moved to
Section 4.
3 | RESULTS
The updated database searches identified 3176 articles (January
2012-July 2016) and 1090 articles (July 2016-June 2017; Figure 1).
After applying inclusion and exclusion criteria, 33 RCTs that reported
on the effects of probiotics in the management of lower GI
symptoms in clinical practice published since January 2012 were
identified, and considered in conjunction with 37 RCTs included in
the original systematic review. Of the 33, 6 publications were found
in the June 2017 update.27-32 These could not be included in the
consensus voting process; however, they were reviewed by the
Steering Committee, which decided that the new evidence provided
in these studies would not alter the results of the Delphi consensus
and so could be included in our publication.
Collectively, the 70 studies investigated a total of 54 different
probiotic products (containing 108 strains either alone or in combi-
nation) at doses ranging from 1 9 106 to 4.5 9 1011 colony-forming
units (CFU) per day, administered as 1, 2 or 3 doses. They predomi-
nantly contained bacteria (mostly lactobacilli and/or bifidobacteria); a
few contained the yeast Saccharomyces. Of the 54 probiotic prod-
ucts, 28 were included in studies published since the original
consensus, and the majority of these (22 of 28; 79%) were new pro-
biotics that had not been evaluated in the original consensus.
TABLE 1 Eligibility criteria for inclusion of publications examining
probiotics in the management of lower GI symptoms
Inclusion criteria Exclusion criteria
Population • Adults (≥18 y old)
• Patients with IBS or
other FGID
• Patients with diarrhoea
as a side effect of
antibiotic treatment
• Patients with no
specific GI diagnosis
• Children
• Disorders such as
inflammatory
bowel disease
and diverticular
disease
• Specialist
populations
(eg patients with
any type of
cancer)
Interventions • Probiotics • Synbiotics
• Sterile preparations
Outcomes • IBS (global symptoms)
• Abdominal pain
• Bloating/distension
• Flatus
• Diarrhoea (treatment)
• Diarrhoea (prevention)
• Constipation
• Bowel habit
• Health-related quality
of life
• Adverse events
• No symptom
scores or clearly
defined response
rates for specific
symptoms
• Symptom clusters
not reported as
pre-specified
primary or
secondary
endpoints
Study design • RCTs
• Placebo-controlled
trials
• Studies with a clear
sample size calculation
• Meta-analysis
• Systematic review
• Studies lasting
<4 wks with <80%
follow-up
• Pooled data
analyses
Date restrictions January 2012-June 2017
Language restrictions English language and
foreign language
publications with an
English abstract
Country Not restricted by country
FGID, functional gastrointestinal disorders; GI, gastrointestinal; IBS, irrita-
ble bowel syndrome; RCT, randomised controlled trial.
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Table 2 provides a summary of the symptoms and indications exam-
ined in the 70 studies.
Product adherence was addressed in 49 of the included studies.
In 42 studies, adherence to the intervention was assessed by count-
ing empty containers or unused test substance returned at the end
of the study and/or by participant self-reporting (in treatment diaries
or during investigator visits). Three of these studies used faecal
recovery of probiotic strains to measure adherence, and publications
from 4 studies did not report the method of assessing adherence.
Where adherence data were reported (38 studies), the level of
adherence was generally high. In the probiotic intervention groups,
the proportion of participants who were adherent to treatment (tak-
ing >80% of doses) was >75%.
The majority of the 70 studies (Table S1)27-96 focused on IBS
(based on Rome I, II or III criteria or physician diagnosis; 34 studies),
antibiotic-associated diarrhoea (13 studies) or diarrhoea-associated
Helicobacter pylori eradication therapy (7 studies). Other conditions
were investigated in 16 studies. Sixty-four studies provided evidence
for the Delphi consensus33-96 (6 were identified after voting was
completed).27-32 The evidence level was graded as “high” for 5 state-
ments, “moderate” for 2, “low” for 4 and “very low” for 2. Table S2
summarises the studies and specific probiotics with evidence for
Search string:
Search run July 2016
(date limit: 2012-2016)
Duplicates: 909 Duplicates: 371
Included for screening: 2267
Included RCTs: 27 Included RCTs: 6
Included RCTs from original review: 37
Included RCTs: 70
Excluded: 2240
Duplicate: 237
Review: 815
Animal/in vivo study: 382
Patient population not of interest: 306
Intervention not of interest: 136
Disease/symptoms not relevant: 51
Outcome not of interest: 37
Non-RCT study: 199
Non-English publication: 22
Abstract-only publication: 37
Inadequately powered trial: 18
Excluded: 713
Duplicate: 80
Review: 204
Patient population not of interest: 139
Intervention not of interest: 63
Disease/symptoms not relevant: 38
Outcome not of interest: 58
Non-RCT study: 83
Abstract-only publication: 46
Inadequately powered trial: 2
Included for screening: 719
Total number of publications identified: 3176
MEDLINE: 1216 hits
Embase: 1960 hits
Publications identified: 1090
MEDLINE: 459 hits
Embase: 631 hits
Search run June 2016
(date limit: 2016-2017)
(yogurt OR yoghurt OR probiotic* OR “lactic acid bacteria” OR “Streptococcus thermophilus” OR “S. thermophilus” OR
“fermented milk” OR Bifidobacter* OR Lactobacill* OR Lactococc* OR “Saccharomyces ” OR “Bacillus mesentericus” OR
“B. mesentericus” OR “ Enterococcus faecalis ” OR “E. faecalis ” OR “Enterococcus faecium ” OR “E. faecium ” OR “Bacillus
clausii” OR “B. clausii ” OR “Clostridium butyricum” OR “C. butyricum ” OR “E. coli Nissle” OR “Escherichia coli Nissle” OR
VSL#3) AND (IBS OR “irritable bowel syndrome” OR “abdominal distension” OR “gas evacuation” OR “visceral hypersensitivity” 
OR bloating OR flatulence OR flatus OR “abdominal pain” OR “digestive symptom” OR “stool consistency”
OR “stool frequency” OR “stool quantity” OR “urgency” OR “faecal incontinence” OR “fecal incontinence” OR defecation OR
“bowel movement” OR “bowel habit” OR transit OR constipation OR diarrhea OR diarrhoea)
F IGURE 1 Flow diagram of literature searches. MEDLINE and Embase searches were performed in July 2016 and June 2017. RCT,
randomised controlled trial
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each consensus statement, together with an indication of whether
the result was a primary or secondary endpoint. A table stating pro-
biotic availability by country in Europe, the USA and China is available at
http://espcg.eu/. For consistency with the original consensus, 10 experts
were invited to participate in the Delphi consensus voting in the update
but for logistical reasons only 8 voted. Consensus was reached for all of
the 16 statements developed in the original Delphi consensus in the first
round of voting (see Figure 2). For each consensus statement, the result
of the first (final) vote and the grade of supporting evidence are given,
followed by a discussion of the evidence. Sometimes, a particular probi-
otic yielded conflicting results for a symptom/problem when it was
investigated in different studies (see Table S2).
3.1 | IBS (global symptom assessment)
Statement 1: specific probiotics help relieve overall symptom burden in
some patients with IBS. Agreement: 100% (6, 12.5%; 5, 87.5%; grade
of evidence for effect: high).
Supportive evidence: Twenty-three studies of 19 different
probiotics evaluated overall symptoms in 3112 patients with IBS. Of
these studies, 15 evaluated overall IBS symptoms as a primary
endpoint, of which 8 reported a significant beneficial effect of 8 dif-
ferent probiotic products (dosed at 3.4 9 107 to 2.5 9 1010 CFU
per day) compared with placebo,32,46,49,56,57,82,93,95 5 reported no
significant differences between 2 specific probiotic treatments and
placebo,30,36,43,80,83 and 2 reported mixed results.54,88 Of the 15
studies, 6 had been published since the original consensus. Two of
the new studies (33%) reported no significant difference, compared
with 3 of the 9 studies (33%) in the original consensus.
Eight studies of 7 different probiotics evaluated overall IBS
symptoms as a secondary endpoint only. Of these, 2 studies found a
significant beneficial effect of 2 different probiotic treatments com-
pared with placebo.44,55 One further dose-ranging study reported a
beneficial effect of the specific probiotic treatment at the 1 9 108
CFU dose, but not at the lower and higher doses tested (1 9 106
and 1 9 1010 CFU).92 Four studies reported no significant differ-
ences between 4 different probiotic treatments and placebo37,66,85,94
and 1 study reported a negative effect of a probiotic treatment com-
pared with placebo.64 Of the 8 studies, 6 had been published since
the original consensus. Four of the new studies (67%) reported no
significant difference or a negative effect, compared with 1 of the 2
studies (50%) in the original consensus.
Statement 2: specific probiotics may help relieve overall symptom
burden in some patients with IBS-C. Agreement: 100% (6, 12.5%; 5,
37.5%; 4, 50%; grade of evidence for effect: very low).
Supportive evidence: Five studies of 4 different probiotics evalu-
ated overall IBS symptoms as a secondary endpoint in 577 patients
with constipation-predominant IBS (IBS-C). Of these, 1 study
reported a beneficial effect of the specific probiotic treatment
(dosed at 2.5 9 1010 at CFU per day) vs placebo.33 Another study
of the same probiotic found a significant improvement from baseline
in the probiotic group but not in the placebo group in a subanalysis
of patients with fewer than 3 bowel movements per week.50 In a
third study with a different probiotic treatment, an improvement
was observed in the composite score of IBS symptoms in the
probiotic group vs the placebo group, but this just failed to reach
statistical significance. However, the total area under the curve of
the composite score of IBS symptoms over 12 weeks was signifi-
cantly lower in the probiotic group than in the placebo group
(P = 0.03).85 Two studies examining 2 different probiotics reported
no significant improvement in symptoms vs placebo.86,92 Of the 5
studies, 2 had been published since the original consensus. Of the 2
new studies, 1 reported no significant improvement, compared with
1 of the 3 studies in the original consensus.
Statement 3: specific probiotics help to relieve overall symptom bur-
den in some patients with IBS-D. Agreement: 100% (6, 12.5%; 5,
37.5%; 4, 50%; grade of evidence for effect: low).
Supportive evidence: Seven studies examining different probiotics
evaluated overall IBS symptoms in 495 patients with diarrhoea-
predominant IBS (IBS-D). Two studies (both included in the original
TABLE 2 Indications and symptoms examined in included studies
Number of studies Indication
Symptom IBS
Functional
GI disorders
Antibiotic
treatment
Helicobacter
pylori eradication
Lactose
intolerance
Healthy/minor
GI symptoms Total
IBS (global symptoms) 30 0 0 0 0 0 30
Abdominal pain 30 2 0 0 2 4 38
Bloating/distension 27 1 0 0 1 4 33
Flatus 15 2 0 0 2 3 22
Diarrhoea (treatment) 4 2 0 0 2 2 10
Diarrhoea (prevention) 0 0 13 7 0 0 20
Constipation 4 3 0 0 0 4 11
Bowel habit 25 2 0 0 1 8 36
Health-related quality of life 20 1 0 0 0 4 25
Total 34 3 13 7 2 11 70
GI, gastrointestinal; IBS, irritable bowel syndrome.
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consensus) evaluated overall IBS symptoms as a primary endpoint,
with 1 study reporting a significant beneficial effect of the specific
probiotic treatment (dose of 1 9 1010 CFU per day) compared with
placebo59 and the other reporting no significant difference.60 Five
studies evaluated overall IBS symptoms as a secondary endpoint
only. Of these, 2 (both included in the original consensus) found a
significant beneficial effect of the specific probiotic treatments,92,96
and 3 (all published since the original consensus) found no significant
0
Statement 1 – original
Statement 1 – update
Statement 2 – original
Statement 2 – update
Statement 3 – original
Statement 3 – update
Statement 4 – original
Statement 4 – update
Statement 5 – original
Statement 5 – update
Statement 6 – original
Statement 6 – update
Statement 7 – original
Statement 7 – update
Statement 8 – original
Statement 8 – update
Statement 9 – original
Statement 9 – update
Statement 10 – original
Statement 10 – update
Statement 11 – original
Statement 11 – update
Statement 12 – original
Statement 12 – update
Statement 13 – original
Statement 13 – update
Statement 14 – original
Statement 14 – update
Statement 15 – original
Statement 15 – update
Statement 16 – original
Statement 16 – update
20 40
Proportion of total votes (%)
60 80 100
Strongly agree
Agree with minor
reservations
Disagree with minor
reservations
Disagree with major
reservations
Strongly disagree
Agree with major
reservations
F IGURE 2 Breakdown of voting agreement for each individual statement in the original and updated Delphi consensus
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difference in the composite IBS symptom score between the pro-
biotic group and the placebo group.65,85,86
3.2 | Abdominal pain
Statement 4: specific probiotics help reduce abdominal pain in some
patients with IBS. Agreement: 100% (6, 37.5%; 5, 50%; 4, 12.5%;
grade of evidence for effect: high).
Supportive evidence: Thirty studies examining 23 different pro-
biotics evaluated abdominal pain in 3771 patients with IBS. Of these
studies, 9 (examining 8 probiotic treatments dosed at 1 9 106 to
1 9 1010 CFU per day) evaluated abdominal pain as a primary end-
point, of which 7 (4 from the original consensus and 3 new studies)
showed a significant beneficial effect of specific probiotic treatments
compared with placebo.44,46,54,74,81,85,92 One of these found no sta-
tistically significant difference in abdominal pain/discomfort between
probiotic and placebo in the overall population but a significantly
greater improvement in the subgroup of patients with IBS-C.85 Two
studies (both included in the original consensus) had mixed results: 1
showed a trend towards a beneficial effect in the weekly symptom
score for abdominal pain (and, in a secondary analysis, abdominal
pain was reduced in a significantly greater proportion of the probi-
otic group than of the placebo group)56 and the other showed no
significant increase in the proportion of patients reporting symptom
relief, but a significantly greater decrease in the abdominal pain
score in the probiotic group than in the placebo group.43
Abdominal pain was evaluated as a secondary endpoint only in
21 studies. Of these, 5 reported a significant beneficial effect of
5 different probiotics33,49,55,82,96 (1 of which33 also showed no
significant effect in another study50), 15 (examining 11 different pro-
biotics) reported no significant effect30,36,37,50,57,59-61,66,80,83,88,93-95
(of which 1 reported a nonsignificant trend in favour of probiotics vs
placebo),95 and another reported a negative effect of the specific
probiotic treatment.64 Of the 21 studies, 9 had been published since
the original consensus. Seven of the new studies (78%) reported no
significant difference or a negative effect, compared with 9 of the
12 studies (75%) in the original consensus.
Abdominal pain was examined in indications other than IBS in
8 studies, each investigating a different probiotic. Of these, 1 study
(included in the original consensus) investigated abdominal pain as a
primary endpoint in individuals with symptoms related to post-
prandial intestinal gas, and found a significant improvement in the
probiotic group compared with the placebo group.58 Seven studies
examined abdominal pain as a secondary endpoint only, with 4 of
these reporting no significant difference among 4 different probiotic
treatments and placebo.47,51,62,69 Another 3 studies (2 examining
2 different probiotics in lactose-intolerant individuals71,73 and
another reporting on a different probiotic in patients with functional
GI symptoms90) found significantly improved abdominal pain from
baseline in the probiotic group, but not in the placebo group. Of the
7 studies, 3 had been published since the original consensus. Of the
3 new studies, 2 (67%) reported no significant difference, compared
with 2 of the 4 studies (50%) in the original consensus.
3.3 | Bloating/distension
Statement 5: specific probiotics help reduce bloating/distension in some
patients with IBS. Agreement: 75% (6, 25%; 5, 12.5%; 4, 37.5%; 3,
12.5%; 2, 12.5%; grade of evidence for effect: moderate).
Supportive evidence: The treatment of bloating/distension in
3561 patients with IBS was evaluated in 27 studies examining
20 different probiotics. Of these studies, 4 (examining 4 different
probiotics, dosed between 1 9 106 and 2.5 9 1010 CFU per day)
evaluated bloating/distension as a primary endpoint. Two studies
(including 1 published since the original consensus) reported a signif-
icant beneficial effect of the specific probiotic treatment vs
placebo,33,55 whereas a further 2 (both included in the original con-
sensus) reported no significant differences.56,61 Bloating/distension
was evaluated as a secondary endpoint only in 23 studies. Of these,
8 reported a significant beneficial effect of 8 different probiotic
treatments44,46,49,50,57,85,92,93 (1 of which50 also showed a beneficial
effect as a primary endpoint in another study33). Of these studies,
some found a significant effect only at one time point,50 after a sin-
gle dose92 or only in patients with IBS-C.85,92 Fifteen studies
reported no significant difference between 12 different probiotic
treatments and placebo30,36,37,59,60,64,66,74,80,82,83,88,94-96 (1 of these
probiotics60 also showed no significant effect on the primary end-
point).61 Of the 23 studies, 11 had been published since the original
consensus. Of the 11 new studies, 9 (82%) reported no significant
difference, compared with 6 of the 12 studies (50%) in the original
consensus.
Six studies investigated the effect of 6 different probiotics on dis-
tension/bloating in indications other than IBS. One of these studies
(included in the original consensus) evaluated symptoms related to
post-prandial intestinal gas as a primary endpoint in healthy individu-
als and reported no significant differences between the probiotic and
placebo groups.58 The remaining 5 studies (examining 5 different pro-
biotics) evaluated distension/bloating as a secondary endpoint. Single
studies reported no significant differences between the probiotic and
control groups in women with mild digestive symptoms,51 patients
with functional GI disorders (FGID),62 healthy individuals with low
defecation frequency and abdominal discomfort,47 and healthy
patients with hard or lumpy stools in the past 2 years.69 The fifth
study, in individuals with lactose intolerance undergoing a hydrogen
breath test, reported significantly reduced bloating in the group
receiving the specific probiotic treatment but no significant improve-
ment in the placebo group.71 Of the 5 studies, 2 had been published
since the original consensus; both of the new studies reported no sig-
nificant difference between probiotic and control groups.
3.4 | Flatus
Statement 6: probiotics tested to date do not help reduce flatus in
patients with IBS. Agreement: 75% (6, 37.5%; 5, 12.5%; 4, 25%; 3,
25%; grade of evidence for effect: low).
Supportive evidence: Overall, 15 studies examining 12 different
probiotics evaluated flatus in 1478 patients with IBS. All 3 studies
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that examined flatus as a primary endpoint (all included in the origi-
nal consensus) showed no significant difference between 3 specific
probiotic treatments and control.54,56,79 Twelve studies examined fla-
tus as a secondary endpoint only. Of these, 8 showed no significant
difference between 8 specific probiotic treatments and con-
trol.33,37,57,59,60,66,85,94 Four studies reported a significant beneficial
effect of 4 different probiotic treatments61,88,92,96 (1 of which61 also
showed no significant effect in another study60); the significant
effect was seen at 1 dose only in 1 of these studies,92 and at week
16 (after follow-up) but not week 8 (end of treatment) in another
study.88 Of the 12 studies, 5 had been published since the original
consensus. Of the 5 new studies, 4 (80%) reported no significant
difference, compared with 4 of the 7 studies (57%) in the original
consensus.
Seven studies examined the effect of 7 different probiotics on
flatus in indications other than IBS. Four of these studies reported
no significant effects on flatus (primary endpoint for 1 probiotic58
and secondary endpoint for 3 other probiotics62,69,73). Three studies
reported a significant benefit of 3 different probiotic treatments on
flatus (secondary endpoint) in women with mild digestive symp-
toms,51 patients with functional GI symptoms90 and individuals with
lactose intolerance undergoing a lactose breath test.71 Of the 7 stud-
ies, 2 had been published since the original consensus; both of the
new studies reported no significant effect on flatus as a secondary
endpoint.
3.5 | Constipation
Statement 7: specific probiotics may help reduce constipation in some
patients with IBS. Agreement: 87.5% (6, 12.5%; 5, 12.5%; 4, 62.5%; 2,
12.5%; grade of evidence for effect: low).
Supportive evidence: Four studies of 4 different probiotics exam-
ined the treatment of constipation as a secondary endpoint in 487
patients with IBS. One study (in patients with IBS-C) reported
significant improvements with the specific probiotic treatment (admin-
istered at 1.25 9 1010 CFU twice daily) vs control for some of the
endpoints (orocaecal transit time, colonic transit time and urgency),
but not others (stool frequency and consistency, straining during
evacuation and feelings of incomplete evacuation).33 The 3 remaining
studies did not detect any statistically significant effects of 3 different
probiotic treatments on the relief of constipation.36,49,74 Of the 4
studies, 2 had been published since the original consensus; both of
the new studies reported no significant effect on constipation.
Seven studies of 7 different probiotics examined constipation in
patients with broader FGID. Of these, 3 studies reported significant
improvements in the relief of constipation, with 1 reporting an
increase in defecation frequency47 and another reporting a signifi-
cant effect of the probiotic on stool consistency vs placebo
(although this study did not show a significant effect of the probiotic
on stool frequency vs placebo).89 The third study did not provide a
between-group statistical analysis; however, the decrease in consti-
pation frequency score was approximately twofold greater in the
probiotic groups than in the placebo group.90 Four studies reported
no significant effect of 4 different probiotic treatments;31,62,68,69
however, 1 of these studies showed a nonsignificant trend in favour
of probiotics.68 Of the 7 studies, 5 had been published since the
original consensus. Of the 5 new studies, 3 (60%) reported no signif-
icant effect, compared with 1 of the 2 studies (50%) in the original
consensus.
3.6 | Bowel habit
Statement 8: specific probiotics help improve frequency and/or consis-
tency of bowel movements in some patients with IBS. Agreement: 100%
(5, 50%; 4, 50%; grade of evidence for effect: moderate).
Supportive evidence: Twenty-five studies examining 20 different
probiotics evaluated bowel habit in 3069 patients with IBS. Two
studies of 2 different probiotics (administered at doses of between
1.3 9 108 and 9 9 109 CFU per day) evaluated bowel habit as a pri-
mary endpoint, with 1 study (included in the original consensus)
reporting no significant difference in weekly defecation frequency
between the probiotic and placebo groups, although a significant
positive effect of the specific probiotic treatment vs placebo was
observed on the secondary endpoints of urgency and feelings of
incomplete evacuation.56 The second study (published since the orig-
inal consensus) found that the number of bowel movements changed
favourably in the probiotic group compared with the placebo
group.32 Of the 25 studies in patients with IBS, 22 evaluated bowel
habit as a secondary endpoint only. Seventeen studies used 1 or
more of 3 main endpoints: stool frequency, stool consistency and
satisfaction with bowel habits. Eleven reported significant beneficial
effects of 11 different probiotics;43,44,46,49,50,55,59,81,82,92,93 1 of
these studies reported a significant improvement in the feeling of
incomplete defecation on completion of 4 weeks of treatment that
was not significant 1 month later.55 Nine studies reported no signifi-
cant effects of 7 different probiotics37,54,57,61,74,80,83,85,95 (1 of
which61 showed no significant benefit on the primary endpoint in
another study60). One found a trend to normalisation of stool consis-
tency (P = 0.058); however, no significant effects on straining and
feelings of incomplete evacuation were observed.33 Another study
reported a significant negative effect of the specific probiotic treat-
ment.64 Of the 22 studies, 7 had been published since the original
consensus. Of the 7 new studies, 4 (57%) reported no significant
effect or a negative effect, compared with 6 of the 15 studies (40%)
in the original consensus.
Two studies (both included in the original consensus) examined
the effects of probiotics on GI transit times. This was assessed as a
primary endpoint in 1 study that reported no difference in GI transit
times between the probiotic and placebo groups.60 A second study
showed significant improvements in the secondary endpoints of
colonic and small bowel transit times in the probiotics vs placebo
groups.33
Eleven studies examining 10 different probiotic treatments
assessed bowel habit in indications other than IBS. Of these, 8 stud-
ies of 8 different probiotics reported that probiotics produced
significant improvements in measures of bowel habit vs
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placebo,31,47,51,63,75,87,89,90 whereas 3 reported no difference
between 3 different probiotics and placebo.68,69,73 Of the 11 studies,
7 had been published since the original consensus. Of the 7 new
studies, 3 (43%) reported no significant difference, compared with
none of the 4 studies in the original consensus.
3.7 | Diarrhoea
Statement 9: probiotics tested to date do not reduce diarrhoea in
patients with IBS. Agreement: 87.5% (6, 62.5%; 5, 12.5%; 4, 12.5%; 2,
12.5%; grade of evidence for effect: very low).
Supportive evidence: Four studies of 4 different probiotics (dosed
at between 4 9 107 and 5.2 9 1010 CFU per day) evaluated the
treatment of diarrhoea as a secondary endpoint in 283 patients with
IBS. Of these, 3 studies (including 1 published since the previous
consensus) reported no difference between specific probiotic treat-
ments and placebo,36,57,59 and another found significant worsening
of diarrhoea with the specific probiotic treatment compared with
placebo.64 Six studies of 6 different probiotics (including 2 studies
published since the previous consensus) evaluated diarrhoea as a
secondary endpoint in indications other than IBS. Specific probiotic
treatment had no significant effect on diarrhoea in elderly nursing
home residents,75 patients with a functional bowel disorder,62 indi-
viduals with functional GI symptoms90 or individuals with hard or
lumpy stools in the past 2 years.69 Two studies (including 1 pub-
lished since the previous consensus) showed a beneficial effect of
2 different probiotics vs placebo on symptoms of diarrhoea, both of
which were in patients with lactose intolerance.71,73
Statement 10: in patients receiving antibiotic therapy, specific
probiotics are helpful as adjuvant therapy to prevent or reduce the
duration of associated diarrhoea. Agreement: 100% (6, 50%; 5, 50%;
grade of evidence for effect: high).
Supportive evidence: Thirteen studies of 10 different probiotics
examined the prevention of antibiotic-associated diarrhoea and/or
reduction in antibiotic-associated diarrhoea in 6091 patients who
received antibiotics (although they were initiated in a hospital
setting, these studies were included because of the relevance of
antibiotic-associated diarrhoea to primary care). Of these, 11 studies
examined antibiotic-associated diarrhoea as a primary endpoint. Six
studies of 4 different probiotics administered at doses of 2 9 109 to
5 9 1010 CFU per day35,38,48,53,72,78 (3 of which tested the same
probiotic treatment)35,48,78 showed a significant reduction in antibi-
otic-associated diarrhoea compared with placebo. One study
reported a significant benefit of the probiotic vs placebo on the
duration of antibiotic-associated diarrhoea only.28 In contrast, 4 stud-
ies of 4 other probiotics reported no evidence that probiotics were
effective in the prevention of antibiotic-associated diarrhoea vs pla-
cebo,34,45,77,84 although 1 of these (an underpowered study) showed
a nonsignificant reduction in antibiotic-associated diarrhoea.84 Of
the 11 studies, 6 had been published since the original consensus.
Of the 6 new studies, 3 (43%) reported no significant effect com-
pared with 1 of the 5 studies (20%) in the original consensus. The 2
studies that assessed antibiotic-associated diarrhoea as only a
secondary endpoint (1 study from the original consensus and 1 new
study) found no difference between the probiotic and placebo
groups.29,76
Statement 11: in patients receiving H. pylori eradication therapy,
specific probiotics are helpful as adjuvant therapy to prevent or reduce
the duration/intensity of associated diarrhoea. Agreement: 100% (6,
87.5%; 5, 12.5%; grade of evidence for effect: high).
Supportive evidence: Seven studies evaluated the effect of 9 differ-
ent probiotics (at doses of between 2 9 106 and 2 9 1010 CFU per
day) on diarrhoea as a side effect of H. pylori eradication therapy in
1480 patients. All the 5 studies examining H. pylori eradication
therapy-associated diarrhoea as a primary endpoint (including 1 study
published since the original consensus) reported a significant benefit
of specific probiotic treatments compared with placebo.39-42,70 How-
ever, the results for 2 of the studies were mixed, with a significant
benefit of the specific probiotic treatment seen after 1 week, but not
2 weeks, in 1 study,70 and significantly fewer days with diarrhoea
and a shorter mean duration of diarrhoea episodes, but no significant
difference in the frequency of diarrhoea episodes, in the probiotic
group compared with the placebo group in another study.42 Two
studies (both published since the original consensus) were identified
that assessed the occurrence of diarrhoea as a secondary endpoint,
and both reported that the addition of probiotics to H. pylori eradica-
tion therapy significantly decreased diarrhoea as a side effect of
treatment.27,52
3.8 | Health-related quality of life
Statement 12: with specific probiotics, improvement of symptoms has
been shown to lead to improvement in some aspects of health-related
quality of life. Agreement: 87.5% (5, 25%; 4, 62.5%; 3, 12.5%; grade
of evidence for effect: low).
Supportive evidence: Health-related quality of life (HRQoL) was
assessed as a primary endpoint in 6 studies with 4 different pro-
biotics (administered at doses of between 5 9 107 and 3 9 1010
CFU per day). Two studies of 2 different probiotics reported a signif-
icantly greater improvement in HRQoL with probiotics, as measured
by an improvement in GI well-being in women with minor GI symp-
toms51 and improvements in scores using the Irritable Bowel
Syndrome Quality of Life (IBS-QOL) instrument in patients with
IBS,65 compared with placebo. One study in patients with IBS-C
reported no significant difference between the probiotic and placebo
groups for the change from baseline in the discomfort dimension
score of the Functional Digestive Disorders Quality of Life (FDDQL)
questionnaire after 3 and 6 weeks of treatment; however, the probi-
otic group had a significantly greater proportion of responders for
the discomfort dimension score than the placebo group at week 3.50
Another study assessed 2 different probiotics in patients with FGID
and found no significant differences between the probiotic and con-
trol groups for the Gastrointestinal Quality of Life Index (GIQLI) total
score and well-being subscales (physical, social and mental; primary
endpoint); however, use of the 36-item Short-Form Health Survey
(SF-36; secondary endpoint) revealed significant improvements in
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physical functioning and/or “role-physical” domains with probiotics,
but no significant changes in the control groups.62 In 1 study, a sig-
nificant reduction in “health-related worry” was observed in patients
with IBS receiving the probiotic treatment vs placebo, but not in
other domains of the IBS-QOL.32 The remaining study in women
with minor GI symptoms found no significant difference in the per-
centage of women reporting an improvement in GI well-being with
probiotics vs placebo.67 Nineteen studies assessed aspects of
HRQoL as secondary endpoints only. Fourteen of these (evaluating
12 different probiotics) found no difference between treatment
groups in measures of HRQoL,30,31,36,54,56-58,80,82,83,85,86,88,92
whereas 5 studies (all in patients with IBS) reported significant bene-
fits of 5 different probiotic treatments for some aspects of
HRQoL.43,46,49,59,93
3.9 | Adverse events
Statement 13: probiotics have a favourable safety profile in patients
with a range of lower GI symptoms typically managed in primary care
or general practice. Agreement: 100% (6, 50%; 5, 37.5%; 4, 12.5%;
grade of evidence for effect: high).
Supportive evidence: Safety data were reported in 50 studies. The
majority of studies revealed no meaningful treatment-emergent
adverse events that were attributed to probiotic use. Forty-three
studies found no relevant differences in safety between 37 specific
probiotic treatments and placebo.30,31,34,35,37,39-42,44,45,47-50,53-57,59-
63,65,68,69,72,74,77,78,80-84,90,92-96 Findings of the remaining 7 studies
(examining 7 probiotic strains) are summarised below.
In 1 study of patients with IBS, 2 patients in the probiotic group
discontinued involvement because of adverse events (moderate nau-
sea and severe exanthema). However, the most frequent adverse
events (fatigue, pruritus and diarrhoea) occurred equally often in the
probiotic and placebo groups.46 In another study of patients with
IBS, 1 participant had a short stay in hospital for cervicobrachialgia 2
weeks after the end of the specific probiotic treatment; however,
there was no organic explanation for this, and the patient continued
in the trial.64 Two patients with IBS treated with probiotics in a third
study reported an itching rash, causing one patient to drop out.36 A
study of patients with IBS-C reported 16 adverse events, which
were judged to be possibly linked to the research or to the study
product by the investigators (10 events were reported in the active
comparator group and 4 in the placebo group).85 The dropout rate
was significantly higher in the probiotic group than in the placebo
group in the final study in patients with IBS (P = 0.048); however,
most of the dropouts were due to noncompliance (n = 5), the
requirement for an antibiotic (n = 5) or worsening of IBS symptoms
(n = 2).86 In a study of healthy athletes, there was a twofold increase
in the number and duration of mild GI symptoms in the probiotic
group compared with the placebo group, although the severity of
these symptoms tended to be lower in the probiotic group than in
the placebo group.91 In a study examining the effects of probiotics
on antibiotic-associated diarrhoea, the incidence of nonserious
adverse events in the probiotic group was 2.0% compared with 0%
in the placebo group. A causality assessment was carried out for all
adverse events, and all were found to be of either probable or possi-
ble association.38
4 | DISCUSSION
This is an update to the evidence-based ESPCG consensus published
in 2013 on the role of probiotics in the management of lower GI
symptoms in adults consulting in primary care. It aims to provide an
overview of the role of probiotics in dealing with patients with a
variety of abdominal problems, and the practical implications of con-
sensus statements for physicians are shown in Table 3.
Data from the 33 newly identified publications, in addition to
those in the original 37, significantly strengthened the evidence base
on the role of probiotics in GI care in just over 5 years. In addition
to information from new RCTs performed in patients with IBS, more
data were identified in patient populations with other GI conditions
(healthy individuals with minor GI complaints, patients with lactose
intolerance and those receiving antibiotics or undergoing H. pylori
eradication therapy). The number of probiotics included in the con-
sensus increased from 32 to 54. After assessment of the evidence,
no new statements were developed, and the wording of the original
statements remained unaltered. The strength of evidence assessed
using the GRADE system was graded as “high” for 5 statements,
“moderate” for 2, “low” for 4 and “very low” for 2. It was maintained
for all 5 statements previously rated as having a high level of evi-
dence and 100% agreement, but reduced for 2 of the 4 statements
previously rated as having moderate evidence and 70%-100% agree-
ment, and 1 of the 3 statements previously rated as having low
TABLE 3 Practical implications of consensus statements for
physicians
Grade of
evidence for
effect Symptoms/indications Meaning for physicians
High Overall symptoms and
abdominal pain in IBS
Prevention or reduction
of diarrhoea in patients
receiving antibiotics
Prevention or reduction
of diarrhoea in patients
receiving Helicobacter
pylori eradication therapy
Probiotics with supportive
evidence for benefit
should be tried
Moderate Bowel movements and
bloating/distension in IBS
Probiotics with supportive
evidence for benefit
could be tried
Low Overall symptoms in IBS-D
Flatus in IBS
Constipation in IBS
Probiotics with supportive
evidence for benefit could
be considered
Very low Overall symptoms in IBS-C
Diarrhoea in IBS
Currently no evidence to
support use of probiotics
IBS, irritable bowel syndrome; IBS-C, constipation-predominant IBS; IBS-
D, diarrhoea-predominant IBS.
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evidence and 60%-90% agreement reflecting the more heteroge-
neous evidence among the studies identified in the updated review.
There may be several explanations for the more diverse results
reflected in the reduced grading of evidence in this review. The field
is challenging owing to the varied nature of bowel symptoms and
abdominal complaints, combined with the relatively undefined mode
of action of the wide range of individual probiotic strains studied. As
well as including a wider range of patients, different probiotics were
assessed in the original and the updated review; of the 32 probiotics
evaluated in the original manuscript, only 6 were assessed in publica-
tions from 2012 onwards. It may be that the 22 new probiotics
evaluated in the updated review were less efficacious in producing a
beneficial response than those assessed in the original manuscript. In
addition, the more recent studies in this review included a larger
number of secondary endpoints than the older studies. Because the
studies were not powered to detect statistical significance in these
endpoints, they may show false negative results.
The reduced strength of evidence for the beneficial effect of
probiotics was reflected in the levels of agreement reached for sev-
eral statements during the wider Delphi voting process. For example,
although consensus was achieved for Statement 1 (“Specific probi-
otics help to relieve overall symptom burden in some patients with
IBS”), the individual levels of agreement were lower in the updated
consensus (“strongly agree”, 12.5%; “agree with minor reservation”,
87.5%) than in the original consensus (“strongly agree”, 40%; “agree
with minor reservation”, 50%; “agree with major reservation”, 10%).
There was a reduction in the number of voters choosing to “strongly
agree” with Statement 13 (“Probiotics have a favourable safety pro-
file in patients with a range of lower GI symptoms typically managed
in primary care or general practice”), despite the updated review
providing no additional evidence for an adverse safety profile of pro-
biotics. This may reflect an awareness of the limited data on long-
term safety in the GI community, despite a lack of published
evidence suggesting safety issues in general populations.
There are, however, statements for which the new evidence
appears to have improved the experts’ confidence in the statements
(Figure 2). For example, the proportion of the voting panel that
“strongly agreed” with Statement 11 (“In patients receiving H. pylori
eradication therapy, specific probiotics are helpful as adjuvant ther-
apy to prevent or to reduce the duration/intensity of associated
diarrhoea”) increased from 60% in the original Delphi consensus to
87.5% in the update. This reflects the results of 2 additional RCTs
identified in the updated systematic review that increased to 7 the
number of RCTs showing a significant beneficial effect of a probiotic
on treatment-induced diarrhoea vs placebo. For Statement 9 (“Probi-
otics tested to date do not reduce diarrhoea in patients with IBS”),
confidence increased for a negligible effect of the probiotic vs
placebo.
When focusing on primary endpoint data, the overall evidence
for the beneficial effect of probiotics was strong. For example,
30 publications reported the effects of specific probiotics vs placebo
on overall lower GI symptoms as a primary or secondary endpoint
(23 in patients with IBS in general [included in Statement 1]); 14 of
these studies reported a significant improvement with probiotics vs
placebo (61%). When publications which reported overall lower GI
symptoms in patients with IBS as a primary endpoint were assessed
(15 studies), 10 found a significant benefit of probiotics vs placebo
(67%). A similar pattern was observed for other symptoms, with a
significant benefit of probiotics compared with placebo being
observed in a greater proportion of studies evaluating the symptom
as a primary endpoint than as any endpoint (abdominal pain: 40% any
endpoint, 78% primary endpoint; constipation: 36% any endpoint,
50% primary endpoint; bowel habit: 56% any endpoint, 63% primary
endpoint; HRQoL: 40% any endpoint, 83% primary endpoint).
Although there is an abundance of data supporting the use of
multiple strains of probiotics for the relief of lower GI symptoms,
large meta-analyses are difficult to carry out owing to the lack of
comparable data available on single specific probiotic strains. Strictly
speaking, they should only be performed on data for the same
organism at comparable doses. There are inherent problems with
meta-analyses that compare combinations of multiple probiotic
strains because they make it difficult to establish the exact role of
individual strains in the management of IBS symptoms and the
extent of their contribution to the efficacy of the composite pro-
biotics. Comparisons of different strains may also dilute any positive
effect of individual probiotics; however, many of these analyses have
shown a beneficial effect of probiotic products.97-102
For meta-analysis, it is more scientifically valid to include RCTs in
which participants are allocated the same single-strain probiotic and
compared with a placebo. Several recent small meta-analyses have
been performed that examine the effects of specific individual pro-
biotics on lower GI symptoms using data from the studies identified
in our systematic review, with results showing a beneficial effect of
probiotics over placebo. A systematic review and meta-analysis eval-
uated the effects of fermented milk with Bifidobacterium animalis
subsp. lactis CNCM I-2494 (DN-173 010) and lactic acid bacteria on
GI discomfort in the general adult population.103 The systematic
review identified 3 RCTs (2 of which were eligible for inclusion in
our review).51,67 Individual data from 598 participants were evalu-
ated in meta-analyses using random-effects models. Results from the
analyses showed that consumption of the specific probiotic was
associated with a significant improvement in overall GI discomfort
(based on responder/nonresponder status) compared with placebo
(odds ratio [OR]: 1.48; 95% confidence interval [CI]: 1.07-2.05). The
study also found that the probiotic was superior to placebo in terms
of reducing digestive symptoms, as measured using a composite
score. A meta-analysis of the effect of Saccharomyces cerevisiae
CNCM I-3856 on GI symptoms in patients with IBS used data from
2 trials74,85 (both of which are included in our review). The authors
reported that patients consuming the probiotic had a significantly
higher chance of reduction in abdominal pain/discomfort
(P = 0.0134) and improvement in stool consistency (P = 0.0003) than
those consuming placebo.104 Another recent meta-analysis examined
the effects of the probiotic Bifidobacterium longum subsp. infantis
35624 in patients with IBS.105 Analysis of data from the 5 studies
that met the inclusion criteria (3 of which are included in our
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review)37,61,92 showed that consumption of single probiotic B. infan-
tis did not impact on GI symptoms, whereas patients who received
composite probiotics containing B. infantis had significantly reduced
abdominal pain and bloating/distention. Other recently published
meta-analyses have examined whether probiotics are of benefit in
the prevention of Clostridium difficile infection, reporting both posi-
tive106 and negative107,108 results.
The current systematic review found strong evidence for the
beneficial effect of probiotics in the prevention of diarrhoea in
H. pylori eradication therapy. All the 6 identified studies showed a
reduction in diarrhoea with probiotic consumption vs placebo. This is
supported by the results of 2 recent meta-analyses that each exam-
ined the effects of a variety of probiotics on H. pylori eradication
rates (primary endpoint) and diarrhoea associated with H. pylori erad-
ication therapy (secondary endpoint).109,110 The first, a meta-analysis
of 13 studies (1 of which is included in the current review)52 involv-
ing a total of 2306 patients, found a reduced risk of diarrhoea in the
probiotic group compared with the placebo group (risk ratio [RR]:
0.51; 95% confidence interval [CI]: 0.31-0.84; P = 0.008).110 Lacto-
bacillus alone (RR: 1.24; 95% CI: 1.12-1.38; P < 0.0001) and multi-
strain probiotics (RR: 1.12; 95% CI: 1.07-1.18; P < 0.00001) were
effective at improving H. pylori eradication rates compared with
placebo. Similarly, the second meta-analysis, which involved
4515 patients from 30 RCTs (5 of which are included in this system-
atic review),40,41,52,70,84 found a significant reduction in the risk of
diarrhoea with the addition of probiotics to standard triple therapy
compared with triple therapy alone (RR: 0.549; 95% CI: 0.391-0.771;
P = 0.001). The addition of probiotics to standard triple therapy also
significantly increased H. pylori eradication rates compared with tri-
ple therapy alone (P < 0.001).109
Our expert consensus panel made 3 general recommendations
for practising clinicians. We recommend that specific probiotics have
a role in the management of some IBS symptoms and can also be
used as an adjunct to conventional treatment. We also recommend
that probiotic strains should be selected based on the patient’s
symptoms, the clinical indication and the available evidence; no
probiotic alleviates the full range of symptoms in IBS. Finally, we
recommend that, when trying a probiotic therapy for a chronic GI
problem, the product should be taken for 1 month; dose selection
should be based on available evidence and manufacturers’ recom-
mendations. These general, pragmatic recommendations for daily
practice were included in the original consensus as Statements 14,
15 and 16, respectively; when the updated evidence was presented
to the voting panel for the current consensus, the level of agreement
with these 3 statements increased from that obtained in the original
consensus, in terms of both overall agreement (which reached 100%
for Statements 14 and 16) and the proportion of respondents voting
to “strongly agree” with the statements (Figure 2 and Table S2).
To enable the current publication to be as up to date as possible
and to avoid a time lag, 6 publications identified in the updated June
2017 database search did not undergo the Delphi consensus pro-
cess. This could have had an impact on the levels of agreement of
the voting panel. However, these publications were reviewed by the
Steering Committee, members of which judged that the new evi-
dence was in line with that previously reported and concluded that
exclusion of the more recent publications would make little or no
difference to the levels of agreement within the Delphi consensus.
As in the original systematic review, only studies that were ran-
domised, placebo-controlled clinical trials of probiotics with suitable
follow-up periods were included in the analysis in an attempt to
obtain the highest quality data. Publications included in both the
original and updated systematic reviews were subjected to quality
assessment using the CASP checklist for RCTs.24 This was carried
out at the suggestion of the Steering Committee to allow the wider
Delphi voting panel to judge the quality of the presented evidence
and to use this to aid their decision-making. The majority of the pub-
lications (67%) were classified as being of “high quality” or above.
Despite the inclusion of adequately powered, high-quality studies,
the results remain diverse. Variations in probiotic strain(s), doses and
modes of administration, the health status of patients, and diet and
concomitant medications (eg antibiotics and antacids) make compar-
isons between probiotics difficult.
Studies that did not strictly fit into the statement categories
were excluded from those statements. For example, 1 study
reported that B. lactis CNCM I-2494 (DN-173 010) produced a sig-
nificant reduction in the “composite score of digestive symptoms”
when it was administered to healthy women reporting minor
digestive symptoms compared with those receiving a control dairy
product (P < 0.05; secondary endpoint).67 However, this study was
not included in the evidence base for Statement 1 because the
statement focused on patients with IBS only. Only a small subset of
the studies identified in the systematic review examined probiotics
in healthy individuals, or patients with lactose malabsorption, other
functional GI problems or mild lower GI symptoms; hence, specific
statements were not prepared for these groups.
Other limitations of the current update that also applied to the
original consensus1 are as follows: the potential for publication bias;
the potential for chance findings in secondary endpoints; the focus
on adults (statements cannot be extended to children); and the pre-
sentation of physicians’ rather than patients’ perspectives. Overall,
the studies identified in this systematic review, which were powered
for specific primary endpoints, reported evidence supporting the
effectiveness of probiotics for the relief of lower GI symptoms
(especially overall GI symptom score, abdominal pain and bowel
habit), improvement of HRQoL, and prevention of both antibiotic-
associated diarrhoea and diarrhoea associated with H. pylori
eradication therapy. For safety outcomes, probiotics were compara-
ble to placebo. When this evidence was presented to clinical experts,
the panel reached consensus.
In the past 5 years, since the original review, the evidence for
the effects of probiotics on lower GI symptoms has doubled. After
evaluation of this evidence using the same rigorous methodology as
before, the statements remain the same, and consensus was
reached. This demonstrates that clinicians can remain confident that
specific probiotics have a role in the management of lower GI
symptoms.
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